RadNet, Inc. RDNT

FY2025 · ended Dec 31, 2025 · Revenue $2.04B, +11.5% YoY · Filed Mar 2, 2026

RadNet, Inc. (RDNT) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.0 billion and a net loss of $18.7 million. As of Jun 30, 2026 it held $726.3 million in cash and investments and $2.2 billion in total debt.

Revenue (TTM)
$2.27B
+18.9% vs year-ago TTM
Net income (TTM)
$-21.12M
-41.5% vs year-ago TTM
Operating cash flow (TTM)
$310.06M
+18.5% vs year-ago TTM
Free cash flow
$30.17M
-32.3% vs prior year
EPS (TTM)
$-0.27
-39.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
77.61M
+4.8% vs prior year
Net cash
$-1.46B
as of Jun 30, 2026
Operating margin
3.1%
FY 2026

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
RDNT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Los Angeles, CA
SEC filer status
Large accelerated filer
SEC CIK
790526
Former names
RadNet, Inc. (until Oct 26, 2026); PRIMEDEX HEALTH SYSTEMS INC (until Nov 21, 2006)

Other Services-Medical Laboratories companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
$2.0B
$1.8B
$1.6B
$1.4B
$1.3B
Operating income
$62.0M
$104.6M
$98.7M
$46.4M
$82.6M
Net income
-$18.7M
$2.8M
$3.0M
$10.7M
$24.7M
Diluted EPS
-$0.25
$0.04
$0.05
$0.17
$0.46
Operating cash flow
$298.8M
$233.0M
$220.9M
$146.4M
$149.5M
Total assets
$3.8B
$3.3B
$2.7B
$2.4B
$2.1B
Total liabilities
$2.4B
$2.2B
$1.9B
$1.9B
$1.7B
Stockholders' equity
$1.1B
$902.3M
$630.7M
$333.0M
$228.9M
Cash and investments
$767.2M
$740.0M
$342.6M
$127.8M
$134.6M
Total debt
$1.9B
$1.7B
$1.5B
$1.5B
$1.4B

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Oct 26, 2026 Oct 26, 2026
8-K Current report
Other events
Aug 14, 2026 Aug 14, 2026
10-Q Quarterly report Aug 10, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 10, 2026 Aug 9, 2026
8-K Current report
Material agreement, New debt, Regulation FD disclosure
Jun 10, 2026 Jun 10, 2026
8-K Current report
Shareholder vote results
Jun 4, 2026 Jun 3, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.